Agios Pharmaceuticals
AGIO
220 hedge funds and large institutions have $2.55B invested in Agios Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 68 increasing their positions, 69 reducing their positions, and 35 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
24% more capital invested
Capital invested by funds: $2.05B → $2.55B (+$494M)
23% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 35
3% more funds holding
Funds holding: 214 → 220 (+6)
2.77% more ownership
Funds ownership: 106.52% → 109.29% (+2.8%)
9% more call options, than puts
Call options by funds: $85.2M | Put options by funds: $78.2M
1% less repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 69
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$77.1M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$57.6M |
| 3 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$27.6M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$18.6M |
| 5 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$16.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$31.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$23.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$22.2M |
| 4 |
O
OrbiMed
New York
|
-$18.6M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$17.2M |
AGIO Hedge Fund Activity: Q3 2025 in Review
220 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2025, worth a combined $2.55B — up 24% from $2.05B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new AGIO positions and 35 closed out — a net gain of 8 holders — while 68 added to existing stakes and 69 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $77.1M. The largest seller was JP Morgan Chase, cutting an estimated $31.8M.
- 220 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2025, up from 214 in Q2 2025.
- Funds reported $2.55B of Agios Pharmaceuticals stock for Q3 2025, up 24% quarter-over-quarter.
- 43 funds opened new Agios Pharmaceuticals positions in Q3 2025 and 35 closed out, a net change of +8 holders.
- The largest Agios Pharmaceuticals buyer in Q3 2025 was Wellington Management Group, an estimated $77.1M added.
- The largest Agios Pharmaceuticals seller in Q3 2025 was JP Morgan Chase, an estimated $31.8M sold.
Based on aggregated 13F filings for Q3 2025.